Inpatient Update

Mason Turner, MD
  • 0,0 (0)
  • MEDICINA

Inpatient Update delivers short, practical reviews of new studies that matter to hospitalists—focused on what actually changes decisions on rounds tomorrow. Efficient, evidence-based, and built for the working clinician. 

Episódios

  1. HÁ 1 DIA

    Fewer Bleeds, Smarter Steroids: Apixaban vs Rivaroxaban and CRP-Guided Steroids for Pneumonia

    Send us Fan Mail With Special Guest Dr. Adam Jaffe In this episode of Inpatient Update, Dr. Mason Turner is joined by hospitalist Dr. Adam Jaffe to tackle two high-impact clinical questions: Is there a clear winner among DOACs? Who actually benefits from steroids in community-acquired pneumonia? Two common decisions. New data. Practice-changing implications.  Articles & PubMed Links Apixaban vs Rivaroxaban for VTE (Head-to-Head RCT) New England Journal of Medicine (2026) Randomized trial (n=2,760) comparing: Apixaban vs Rivaroxaban Population: Acute VTE Excluded: active cancer, extreme obesity, other anticoagulation indications Key Findings ↓ Clinically significant bleeding with apixaban ~54% relative risk reduction NNT ≈ 27 ↓ Major bleeding (0.4% vs 2.4%) No difference in: Recurrent VTE Mortality Interpretation Same efficacy Less bleeding with apixaban Takeaway → For new starts: Apixaban is the preferred DOAC pubmed: https://pubmed.ncbi.nlm.nih.gov/41812192/ Corticosteroids in Community-Acquired Pneumonia (IPD Meta-analysis) Lancet Large meta-analysis (n=3,224 across 8 RCTs) Compared: Steroids vs Placebo Primary Outcome: 30-day mortality Absolute risk reduction: 2.2% NNT = 46 🔑 The Key Insight: CRP Matters When stratified by inflammation: CRP >200 Mortality: 13% → 6% Absolute risk reduction ≈ 7% NNT ≈ 14 CRP 200) → Routine use in all pneumonia is not supported pubmed: https://pubmed.ncbi.nlm.nih.gov/39892408/ Practice-Changing Takeaways DOACs: Apixaban > rivaroxaban for bleeding Same clot prevention → choose apixaban for new starts Pneumonia: Steroids may reduce mortality — but only in the right patient CRP can help identify who benefits Clinical Pearls The difference between DOACs is no longer “vibes” — we now have head-to-head data Most steroid benefit in pneumonia appears inflammatory-driven, not severity-driven CRP — often ignored — may actually guide meaningful decisions here Bottom Line If you change nothing else this week: Start apixaban for new VTE patients In pneumonia, check a CRP — and consider steroids if >200 Fewer bleeds. Smarter steroids. Better outcomes.

    28 min

  2. 22 DE ABR.

    Asymptomatic Hypertension & Viral Pneumonia — Stop Overtreating

    Send us Fan Mail With Special Guest Dr. Austin White In this episode of Inpatient Update, Dr. Mason Turner is joined by hospitalist Dr. Austin White to tackle two everyday controversies that affect nearly every admission: Asymptomatic inpatient hypertension — are PRN antihypertensives helping… or harming? Antibiotics for pneumonia with a positive viral panel — do these patients actually benefit? Practical take-homes, real-world night shift scenarios, and what to change on rounds tomorrow.  Articles & PubMed Links:As-Needed Blood Pressure Medication and Adverse Outcomes in VA Hospitals JAMA Internal Medicine (2025) Retrospective cohort of hospitalized patients comparing: Received PRN antihypertensives vs No PRN treatmentKey Findings  ↑ Acute kidney injury (HR ~1.23)  ↑ Rapid BP drops >25% (HR ~1.5)  ↑ Composite outcome (MI, stroke, death) (HR ~1.6) IV meds worse than oral Interpretation  Treating asymptomatic inpatient hypertension is associated with harm, not benefit  Likely mechanism: overcorrection → hypoperfusionTakeaway For asymptomatic hypertension, especially overnight: → Don’t reflexively treat the number → Focus on symptoms and underlying cause Pubmed: https://pubmed.ncbi.nlm.nih.gov/39585709/  Antibiotics for Pneumonia with Positive Viral Testing Multicenter Retrospective Study (2015–2024) Compared: Minimal antibiotics (0–1 day) vs Standard CAP treatment (5–7 days)In patients with:  Positive viral assay  Clinical pneumonia (hypoxia, tachypnea, imaging) Key Findings No difference in:  Mortality  ICU admission  Length of stay  No clear harm signal either Interpretation  Many patients with “pneumonia” + viral panel likely have pure viral illness Routine antibiotics do not improve outcomesTakeaway → If viral etiology fits the clinical picture,  don’t routinely continue antibiotics Pubmed: https://pubmed.ncbi.nlm.nih.gov/41378862/  Practice-Changing TakeawaysHypertension: Treat the patient, not the number  PRN antihypertensives for asymptomatic BP may cause harm Viral pneumonia: Positive viral panel + consistent story → hold antibiotics Reassess if clinical course worsens Both topics highlight: → We often overtreat out of habit, not evidenceClinical Pearls from the Episode The body tolerates transient high BP better than rapid drops  Overcorrection → ↓ cerebral perfusion → bad outcomes  Viral infections (even “mild” ones like rhino/adenovirus) can cause severe illness Antibiotic stewardship = patient safety, not just resistance Bottom LineIf you change nothing else this week:  Stop reflexively treating asymptomatic inpatient hypertension  Stop reflexively continuing antibiotics for viral pneumonia Less intervention. Better outcomes.

    29 min

  3. 8 DE ABR.

    Simple, High-Impact Changes Hospitalists Are Missing (SHM 2026 Takeaways)

    Send us Fan Mail With Special Guest Dr. Emily Reams In this special episode of Inpatient Update, Dr. Mason Turner is joined by hospitalist Dr. Emily Reams to break down the most practice-changing takeaways from SHM Converge 2026. No fluff — just what you can start doing on rounds tomorrow. Topics include:  Flu shots in heart failure — real mortality benefit  Stopping aspirin in patients on DOACs  Anticoagulation in AFib despite fall risk  Naltrexone for alcohol use disorder — start inpatient  Phenobarbital for withdrawal — coming soon  Metformin in the hospital — dogma challenged  Transfusion thresholds in MI  “Things We Do for No Reason” highlights Practical take-homes and what to actually change this week. Practice-Changing Highlights 💉 Flu shots in heart failure NNT ≈ 17 for death/readmission → Vaccinate before discharge during flu season 💊 Stop aspirin with DOACs ↑ bleeding and mortality without benefit → Stop aspirin ~6–12 months post-stent (most patients) 🧠 AFib + fall risk Benefit >> risk (would need >450 falls/year to offset) → Don’t withhold anticoagulation for falls alone 🍺 Alcohol use disorder Naltrexone: start before discharge → ↓ cravings, ↓ readmissions Phenobarbital: increasing use, likely future standard 💊 Metformin inpatient May be safe in select patients → Consider if GFR ≥30 and no lactic acidosis 🩸 Transfusion in MI Target Hgb ~10 may reduce mortality → Evolving — keep on radar 💊 Anticoagulation updates  Apixaban preferred over rivaroxaban  Reduce dose after 3–6 months for VTE  → Reassess dosing routinelyBig Picture  Biggest wins = simple changes Often: stop meds or use basics better Hospitalists have high-impact touchpoints If You Change Nothing Else This Week  Give flu shots in heart failure  Stop aspirin in DOAC patients (when appropriate)  Anticoagulate AFib despite fall risk  Start naltrexone before discharge Small changes. Massive reach. Real impact.

    1h

  4. 26 DE MAR.

    De-escalating Sepsis Antibiotics & When to Pull the IV (w/ Nicholas Linde, PA)

    Send us Fan Mail Episode 5: De-escalating Sepsis Antibiotics & When to Pull the IV w/ Nicholas Linde, PA With Special Guest Nicholas Linde, PA In this episode of Inpatient Update, Dr. Mason Turner is joined by hospitalist PA Nick Linde to tackle two everyday decisions that impact nearly every inpatient service: De-escalating broad-spectrum antibiotics in sepsis — is it safe to stop vancomycin and zosyn earlier than we think? Routine peripheral IV use — are we leaving IVs in too long and causing harm? Practical take-homes, real-world cases, and what to change on rounds tomorrow. Articles & PubMed Links Antibiotic De-escalation in Adults Hospitalized With Community-Onset Sepsis JAMA Internal Medicine (2026) Compared: Continue broad-spectrum antibiotics beyond day 4 vs De-escalate at day 4 Key Findings No difference in 90-day mortality (OR ≈ 1.0) Shorter hospital length of stay   ~1 day shorter (MRSA de-escalation) ~2 days shorter (pseudomonal de-escalation) No clear harm signal with de-escalation Takeaway In clinically improving patients with negative or non-MDR cultures, early de-escalation at day 4 is safe and reduces hospital stay. Pubmed: https://pubmed.ncbi.nlm.nih.gov/41428290/  Things We Do for No Reason™: Routinely Maintaining Intravenous Access in Hospitalized Patients Journal of Hospital Medicine (2026) Key Points ~25% of inpatient IVs are idle (not in use) Peripheral IVs contribute to morbidity: ~20% of MSSA bacteremia When to Remove No IV medications or fluids needed Clinically stable patient Oral alternatives available When to Keep High risk of decompensation Anticipated procedures or IV contrast Ongoing electrolyte replacement or IV therapy Takeaway Peripheral IVs are not benign — if you’re not using it, seriously consider removing it. Pubmed: https://pmc.ncbi.nlm.nih.gov/articles/PMC12865233/  Practice-Changing Takeaways Sepsis: At day 4, reassess. If cultures are negative and patient improving, de-escalate broad-spectrum antibiotics. IVs: “Use it or lose it.” Idle IVs carry real risk — don’t leave them in by default. These are high-frequency decisions → small changes = big impact.

    39 min

  5. 11 DE MAR.

    Faster Hypernatremia Correction & Long-Acting Antibiotics for Staph Bacteremia (w/ Dr. Kevin Baker)

    Send us Fan Mail Episode 4: Faster Hypernatremia Correction & Long-Acting Antibiotics for Staph Bacteremia With Special Guest Dr. Kevin Baker In this episode of Inpatient Update, Dr. Mason Turner is joined by hospitalist Dr. Kevin Baker to discuss two studies that challenge long-held dogma in inpatient medicine: Faster correction of hypernatremia — is the traditional “go slow” rule actually harming patients?Dalbavancin for Staph aureus bacteremia (DOTS Trial) — can two long-acting antibiotic injections replace weeks of IV therapy and PICC lines?Practical take-homes, real-world discussion, and what to change on rounds tomorrow (with a couple of bourbons). Articles & PubMed Links Clinical outcomes of early fast compared to slow sodium correction rate in adults with severe hypernatremia: A comparative effectiveness study Journal of Critical Care (2025) Key Findings Faster correction associated with lower 30-day mortalityShorter ICU length of stayShorter hospital length of stayNo signal for neurologic complications from rapid correctionSupporting data from prior studies: 2023 JAMA observational cohort Faster correction associated with lower mortality No neurologic complications reported2025 Journal of Critical Care meta-analysis Faster correction not associated with worse outcomesTakeaway For adult hypernatremia, especially in critically ill patients, more aggressive correction appears safe and may improve outcomes. Pubmed: https://pubmed.ncbi.nlm.nih.gov/41240509/ Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial JAMA 2025 Compared: Standard Therapy 4–8 weeks IV antibioticsCefazolin / anti-staphylococcal penicillin (MSSA)Vancomycin or daptomycin (MRSA)vs Dalbavancin Strategy 1500 mg IV day 11500 mg IV day 8Long-acting lipoglycopeptide with ~14-day half-life, allowing completion of therapy without PICC lines. Population Complicated Staph aureus bacteremiaKey Results Clinical efficacy: Dalbavancin: 73%Standard therapy: 72%Microbiologic success: Dalbavancin: 98.8%Standard therapy: 96.3%Met criteria for non-inferiority. Takeaway For selected patients with cleared Staph aureus bacteremia, two doses of dalbavancin may replace weeks of IV antibiotics and PICC lines. Potential advantages: Avoids central line complicationsSimplifies discharge planningUseful in patients with difficult social situations or IV access concernsPubmed: https://pubmed.ncbi.nlm.nih.gov/40802264/ Practice-Changing Takeaways Hypernatremia: Faster correction appears safe in adults and IMPROVES mortality.Staph bacteremia: Long-acting dalbavancin offers a PICC-free alternative for completing therapy in selected patients.Hospital medicine continues to move toward shorter and simpler antibiotic strategies.

    34 min

  6. 25 DE FEV.

    Stop the Aspirin in CAD? Shorter Antibiotics for Bacteremia? (with Dr. Andres Ospina)

    Send us Fan Mail In this episode of Inpatient Update, Dr. Mason Turner is joined by Dr. Andres Ospina, fellow hospitalist, to discuss two recent trials with immediate impact on hospital practice: Aspirin plus anticoagulation in chronic coronary disease (AQUATIC Trial) — does keeping aspirin help or harm when long-term anticoagulation is started?Seven vs fourteen days of antibiotics for bloodstream infection (BALANCE Trial) — can we safely cut bacteremia treatment in half?Practical take-homes, clear links to the evidence, and what to change on rounds tomorrow. Articles & PubMed Links Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC Trial) New England Journal of Medicine (October 2025) Key Findings: Higher morbidity and mortality with dual therapy (HR 1.53)Bottom Line: In stable CAD >6 months from revascularization, if anticoagulation is started, stop the aspirin. Pubmed: https://pubmed.ncbi.nlm.nih.gov/40888725/ Antibiotic Treatment for Bloodstream Infection (BALANCE Trial) New England Journal of Medicine (November 2024) Multicenter, randomized, non-inferiority trial (n≈3,600) Bottom Line: In uncomplicated bacteremia with source control and no severe immunocompromise, 7 days is non-inferior to 14. Pubmed: https://pubmed.ncbi.nlm.nih.gov/39565030/ Practice-Changing Takeaways Stable CAD + new anticoagulation? Stop aspirin if >6 months from PCI/CABG.Uncomplicated bacteremia? Seven days of antibiotics is sufficient in most cases (excluding Staph aureus and deep-seated infection).

    26 min

  7. 12 DE FEV.

    Pilot Episode 2: Phenobarbital for DTs, Conservative Dialysis for AKI, and Postop Transfusion Thresholds

    Send us Fan Mail In Episode 2 of Inpatient Update, your host, Dr. Mason Turner, breaks down three studies that could change what you do on rounds tomorrow: Phenobarbital for alcohol withdrawal — fewer admissions and shorter ED stays during the IV lorazepam shortage natural experiment.Conservative dialysis in AKI requiring RRT (LIBERATE-D) — less routine dialysis, more kidney recovery?Postoperative transfusion thresholds in high–cardiac-risk patients (TOP Trial) — is 7 still enough?Articles & PubMed Links Fewer Admissions, Shorter Stays: Phenobarbital Use for Alcohol Withdrawal in the Emergency Department Academic Emergency Medicine (2025) PubMed: https://pubmed.ncbi.nlm.nih.gov/41147831/A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury (LIBERATE-D Trial) JAMA ( 2026) PubMed: https://pubmed.ncbi.nlm.nih.gov/41201895/Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial JAMA (2025) PubMed: https://pubmed.ncbi.nlm.nih.gov/41205227/REACH OUT: Have insight into inpatient medicine?  Article suggestion?  Interested in being a guest? Email or DM me.  Follow and subscribe wherever you listen so you never miss the next update.

    28 min

  8. 3 DE FEV.

    Pilot Episode: ERCP Antibiotics, Apixaban Dose in Cancer, and Early Beta-Blockers in Cirrhosis

    Send us Fan Mail In this pilot episode of Inpatient Update, your host, Dr. Mason Turner, breaks down three clinically relevant studies that could change how you practice tomorrow on the wards: Pre-ERCP antibiotic prophylaxis — does it reduce post-procedure infections in biliary obstruction?Reduced-dose apixaban after 6 months in cancer-associated VTE — noninferior and potentially safer?Early initiation of beta-blockers in cirrhosis with uncomplicated ascites — early signals of benefit.Practical take-homes, clear links to evidence, and what to tell your team on rounds. Articles & PubMed Links Is Antibiotic Prophylaxis Warranted in All Patients With Biliary Obstruction Undergoing Endoscopic Retrograde Cholangiopancreatography?: A Systematic Review and Meta-Analysis PubMed: https://pubmed.ncbi.nlm.nih.gov/40961256/ Extended Reduced-Dose Apixaban for Cancer-Associated VTE (API-CAT) PubMed: https://pubmed.ncbi.nlm.nih.gov/40162636/ Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial) PubMed: https://pubmed.ncbi.nlm.nih.gov/40689908/

    18 min
  • 8 episódios

Sobre

Inpatient Update delivers short, practical reviews of new studies that matter to hospitalists—focused on what actually changes decisions on rounds tomorrow. Efficient, evidence-based, and built for the working clinician. 

Informações

  • Criado por
    Mason Turner, MD
  • Anos de atividade
    2 mil
  • Episódios
    8
  • Classificação
    Livre
  • Copyright
    © 2026 Inpatient Update
  • Site do podcast
    Inpatient Update

Você também pode gostar de